CTOs on the Move

EnviroLogix

www.envirologix.com

 
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.envirologix.com
  • 500, Riverside Industrial Parkway
    Portland, ME USA 04103
  • Phone: 866.408.4597

Executives

Name Title Contact Details

Similar Companies

Senti Bio

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.

CAPARIO

CAPARIO is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aulos Bioscience

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

Cardea

Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information

biOasis Technologies Inc

biOasis Technologies Inc., an early stage biopharmaceutical company, engages in the research, development, and commercialization of technologies and products for the diagnosis and treatment of central nervous system diseases and disorders. The company develops Transcend program, a protein vector, which is a proprietary carrier for the transport of therapeutic agents across the blood brain barrier for treatment of a range of neurological, oncological, and infectious disease applications; and Cognitest, a proprietary in vitro diagnostic assay for Alzheimer’s disease. It has a collaborative research agreement with the University of British Columbia to assist the company in development of an enzyme linked immunosorbent assay to detect levels of p97 in blood for the purpose of evaluating the correlation between p97 and Alzheimer’s disease. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.